Peptide Relay

Gathering the record

Loading the next view…

Relay is organizing the evidence and source boundaries.

Compound library

Peptide analog

Synthetic alpha-MSH analogue and predominant MC1R agonist

Afamelanotide

Narrow product-specific FDA approval

A name commonly used for afamelanotide. Its approved implant treats a rare disorder that makes sunlight painful.

6-minute readFull profile reviewed July 25, 2026

Evidence is explained by question. Dosing references show their own check dates.

60-second overview

Afamelanotide at a glance

Why people look into it, what studies found, and what is still unknown.

Why people look into it: Pain-free light exposure in that condition, pigmentation, and other specific skin questions.
What studies found: Studies found more pain-free light exposure with the approved implant. A small vitiligo study also used light therapy, so it could not isolate the implant's effect.
What is still unclear: The implant is not a cosmetic tanning product. Its evidence does not establish benefits or safety for separately prepared MT-1 injections.

About the evidence and review date

Educational information only. Evidence reviewed through July 25, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.

Research questions

Why people research it

Each label shows how much evidence supports that question.

Pain-free light exposure in adult EPPApproved use
Fewer or less severe phototoxic reactions in EPPSupported by human studies
Skin pigmentationSupported by human studies
Vitiligo repigmentation with narrowband UV-BEarly human evidence
EPP-related liver protectionEarly human evidence
Cosmetic tanning or general sun protectionNot demonstrated

What studies show

What the evidence supports

The research behind the answer

Two randomized, double-blind, placebo-controlled EPP trials involving 168 adults, supported by the current FDA label and postauthorization cohorts of 117 and 200 patients.

See each finding and its sources (12)

Mechanistic rationale

Melanotan I, MT-1, and afamelanotide refer to the same synthetic alpha-MSH analogue, while SCENESSE is one specific regulated implant product.

Afamelanotide is also called NDP-alpha-MSH and Melanotan I. SCENESSE contains 16 mg of afamelanotide in a sterile bioresorbable controlled-release implant.

A shared ingredient name does not make powders, nasal products, injections, salts, concentrations, or seller-labeled MT-1 materials equivalent to SCENESSE.

FDA prescribing informationDescription and dosage form

Mechanistic rationale

Afamelanotide predominantly activates MC1R and increases eumelanin production independently of UV exposure.

MC1R signaling in melanocytes increases darker eumelanin pigment. This explains the pigmentation effect and contributes to the EPP treatment rationale.

A mechanism is not proof of benefit for tanning, sunburn prevention, skin cancer prevention, vitiligo, or another condition. Pigmentation is not a substitute for sun protection.

FDA prescribing informationClinical Pharmacology

Controlled human study

SCENESSE has a narrow FDA-approved indication for increasing pain-free light exposure in adults with EPP.

The approval is tied to the named 16 mg implant, adult EPP population, professional implantation, and product label.

The approval does not cover cosmetic tanning, vitiligo, children, general photoprotection, liver disease, or non-SCENESSE MT-1 products.

FDA prescribing informationIndications and Usage

Peer reviewedControlled EPP trial outcomes

Controlled human study

Controlled EPP trials demonstrated more pain-free sunlight exposure and improved quality of life with the 16 mg implant.

Both pivotal trials favored afamelanotide for pain-free sunlight exposure; the European trial also recorded fewer phototoxic reactions.

The trials used different sunlight measures and rare-disease populations. Their results apply to EPP and a controlled-release implant, not general tanning or sun tolerance.

FDA prescribing informationClinical Studies

Peer reviewedPrimary endpoints and quality-of-life results

Other human evidence

Real-world EPP cohorts report improved time outdoors or quality of life, but they do not provide randomized confirmation.

A 117-person practice cohort reported more time outside, and a 200-person German registry reported better quality of life and high treatment continuity.

These studies lacked untreated concurrent comparator groups and are vulnerable to reporting, seasonal, selection, and sponsor-related bias.

Peer reviewedPostauthorization outcomes

Peer reviewedQuality of life and treatment continuity

Controlled human study

A small randomized study found faster and greater vitiligo repigmentation when afamelanotide implants were added to narrowband UV-B.

The combination outperformed UV-B alone in 55 adults, especially among the darker skin phototypes studied.

This was off-label combination research, not afamelanotide monotherapy, and it does not establish an approved vitiligo treatment or results for every skin type.

FDA prescribing informationApproved indication does not include vitiligo

Peer reviewedDay 168 repigmentation and time-to-response results

Controlled human study

Pigmentation is a known pharmacologic effect, not proof of cosmetic-tanning approval or protection from ordinary UV injury.

The label documents generalized pigmentation, skin hyperpigmentation, and darkening of existing nevi and freckles while still requiring sun and light protection.

No FDA-approved cosmetic-tanning indication was identified. Darker appearance does not establish an SPF, replace sunscreen, or show reduced skin-cancer risk.

FDA prescribing informationPharmacodynamics, Warnings and Precautions, and Patient Counseling

Controlled human study

Important known safety findings include implant-site reactions, nausea, pigment changes, and rare serious hypersensitivity reactions.

In controlled EPP trials, implant-site reactions occurred in 21% with SCENESSE versus 10% with vehicle and nausea in 19% versus 14%. Postmarketing anaphylaxis has been reported.

Trial rates do not capture every rare or long-term event. The current label contraindicates SCENESSE after severe hypersensitivity and recommends twice-yearly full-body skin examinations.

FDA prescribing informationContraindications, Warnings and Precautions, Adverse Reactions, and Postmarketing Experience

Controlled human study

The approved SCENESSE label describes a clinician-placed implant, not a self-injection or reconstituted peptide.

The implant is placed subcutaneously by a trained healthcare professional under an aseptic procedure every two months for the approved EPP use.

This is product-specific label information, not an individualized recommendation and not a route, dose, cycle, or conversion for powders, vials, sprays, or other MT-1 products.

FDA prescribing informationDosage and Administration

Other human evidence

Observational liver findings in EPP are suggestive and do not establish an approved liver-protection benefit.

A 70-person retrospective study associated implant exposure with lower protoporphyrin and selected liver-test values.

The study was retrospective, nonrandomized, and subject to confounding. SCENESSE is not FDA approved to prevent or treat EPP-related liver disease.

FDA prescribing informationIndications and Usage

Peer reviewedRepeated-measures liver and PPIX analyses

Other human evidence

Afamelanotide treatment alone did not correct vitamin-D deficiency in a 230-person EPP cohort.

Average vitamin-D levels did not significantly increase with afamelanotide alone, even though the treatment can increase pain-free light exposure.

This observational result is specific to vitamin-D laboratory values in EPP and should not be turned into individualized supplement guidance.

Peer reviewedLongitudinal vitamin-D analysis

Controlled human study

SCENESSE storage instructions do not create a general MT-1 reconstitution or stability standard.

The sealed implant is refrigerated at 2°C to 8°C and protected from light. It is a finished bioresorbable product and requires no reconstitution.

The label cannot validate identity, sterility, concentration, excipients, stability, beyond-use dating, or reconstitution conditions for material supplied as powder, solution, spray, or an unapproved implant.

FDA prescribing informationHow Supplied, Storage and Handling

Risks & unknowns

What needs caution

Reported side effects

Important known safety findings include implant-site reactions, nausea, pigment changes, and rare serious hypersensitivity reactions.

Controlled human evidence

Trial rates do not capture every rare or long-term event. The current label contraindicates SCENESSE after severe hypersensitivity and recommends twice-yearly full-body skin examinations.

Open source

Urgent medical evaluation

In controlled EPP trials, implant-site reactions occurred in 21% with SCENESSE versus 10% with vehicle and nausea in 19% versus 14%. Postmarketing anaphylaxis has been reported.

Controlled human evidence

Urgent-action language is product- and context-specific. Consult the linked current label or source rather than generalizing it to other formulations.

Open source

Missing reports do not establish safety. Findings apply to the product, route, amounts, population, comparison, and follow-up studied.

Side-effect frequency, study withdrawals, and gaps

How often side effects occurred

Important known safety findings include implant-site reactions, nausea, pigment changes, and rare serious hypersensitivity reactions.

Controlled human evidence

Low-frequency estimates are sensitive to sample size, follow-up, ascertainment, formulation, and population.

Open source

Why people stopped in studies

Relay has not verified which side effects led people to stop treatment in studies.

Evidence boundary

This is an evidence gap, not proof that discontinuations did not occur.

Warning information

Relay has not verified a compound-specific warning summary for this profile.

Evidence boundary

FDA approved only as the SCENESSE 16 mg bioresorbable subcutaneous implant to increase pain-free light exposure in adults with EPP. Other products, formulations, populations, and uses are not covered by that approval. How long-term rare safety, pigmentary surveillance, pediatric use, off-label skin indications, liver outcomes, and non-implant formulations compare with the well-defined SCENESSE evidence record.

Dosing references

Dosing & preparation

Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.

Route: Implant · A product placed under the skin by a healthcare professional

Approved product · U.S. prescribing informationWhat this means

Instructions from the named approved product’s prescribing information. They apply to its stated formulation, route, use, and population.

Afamelanotide · Scenesse implant label

Scenesse is labeled for adults with erythropoietic protoporphyria and a history of phototoxic reactions.

Amount in this source: One 16 mg implant
Frequency: Every 2 months
Treatment period: Ongoing indication-specific treatment

Afamelanotide · Scenesse implant label
Stage / period	Amount in source	Frequency
Ongoing indication-specific treatment	One 16 mg implant	Every 2 months

An implant is not a powder-vial injection. This label does not establish a tanning injection schedule for products sold as MT-1.

Scenesse · U.S. prescribing information Prescribing information · Dosage and administrationThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.

Formulation & handling · Implant

Scenesse is a finished implant. It is not reconstituted or measured with an insulin syringe.

Starting dose, maintenance, and trial targets explained

Starting dose: the amount used at the beginning of the named label schedule or trial.

Maintenance: the ongoing amount described by that product label.

Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.

Other source records, populations, and limits · all routes

Product-specific regulatory record

SCENESSE controlled-release implant

Amount in this source: See the named dosing references above; this additional source record does not add a verified amount.
Frequency: One implant every 60 days under the trial protocols
Route: Clinician-placed subcutaneous implant
Duration: 180 days in the U.S. trial and 270 days in the European trial

Population, study design, and limitations

Two pivotal controlled trials evaluated the regulated afamelanotide implant in adults with erythropoietic protoporphyria.

Population: Adults with erythropoietic protoporphyria

Design: Two multicenter, randomized, double-blind, placebo-controlled trials

The trials used a specific controlled-release implant in a rare-disease population.
The findings do not establish cosmetic tanning, ultraviolet protection, self-injection, or equivalence to reconstituted material.

Afamelanotide for Erythropoietic ProtoporphyriaSelected study record

Mechanisms

How it works

Afamelanotide is a synthetic tridecapeptide analogue of alpha-melanocyte-stimulating hormone that binds predominantly to MC1R and increases cutaneous eumelanin independently of UV exposure. Two randomized EPP trials demonstrated longer pain-free sunlight exposure and improved quality of life with a 16 mg controlled-release implant. Postauthorization cohorts support real-world effectiveness but lack concurrent untreated controls. A small randomized study found faster vitiligo repigmentation only when the implant was combined with narrowband UV-B. Liver and vitamin-D findings remain observational. The current label adds a serious-hypersensitivity boundary and recommends twice-yearly skin monitoring.

Why this matters

A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.

Signals and targets

Proposed biological steps

Predominant MC1R agonism
Increased eumelanin production
Alpha-MSH analogue signaling

Research reference

How mature is the evidence?

A reference for the studies, populations, and routes behind this profile.

Research depthMature implant-specific human record

Afamelanotide has controlled pivotal trials, an approved product, pharmacokinetic data, postauthorization cohorts, and investigational dermatology research.

Why this matters

Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.

Evidence confidenceVery high for the approved EPP endpoint

Controlled trials and current labeling support increased pain-free light exposure in adults with EPP; confidence does not extend to cosmetic tanning or unapproved formulations.

Why this matters

Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.

Strongest evidenceTwo controlled pivotal EPP trials plus current FDA labeling

Why this matters

The strongest evidence type shows what the best-supported conclusions are actually based on.

Human evidenceDirect and strong for the 16 mg controlled-release implant in adult EPP

Why this matters

Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.

Route-specific record

Which product or study does this describe?

SCENESSE controlled-release implantAmounts and schedules below belong to this source record.Afamelanotide for Erythropoietic Protoporphyria Administration reference reviewed Aug 5, 2026

Route studiedClinician-placed subcutaneous implant

Schedules studiedOne implant every 60 days under the trial protocols; 180 days in the U.S. trial and 270 days in the European trial

Amounts studiedWithheld: this record provides research context without a transferable amount

Why this matters

These are exposures used in cited research for a specific route and population—not an instruction for an individual.

Half-lifeNot established for this exact editorial record

Why this matters

Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.

Route evidenceTwo pivotal controlled trials evaluated the regulated afamelanotide implant in adults with erythropoietic protoporphyria.

Why this matters

Evidence can change by administration method. Findings from one route should not automatically be applied to another.

Evidence boundary: The trials used a specific controlled-release implant in a rare-disease population. The findings do not establish cosmetic tanning, ultraviolet protection, self-injection, or equivalence to reconstituted material. Amounts shown describe cited research exposure—not a dosage recommendation.

Studies

Study-by-study record

Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.

Why this matters

A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.

Controlled human studyPeer reviewed

Afamelanotide for Erythropoietic Protoporphyria

Peer reviewed

PhasePivotal controlled trials

Population168 participants

Duration180 days in the U.S. trial and 270 days in the European trial

Design and population

Two multicenter, randomized, double-blind, placebo-controlled trials

Adults with erythropoietic protoporphyria

Outcomes measured

Pain-free direct sunlight exposure
Phototoxic reactions
Disease-specific quality of life
Adverse events

What was reported

Pain-free sunlight exposure was longer with afamelanotide in both trials. The European trial also recorded fewer phototoxic reactions, and quality-of-life measures improved in both studies.

Study administration and important limits

Study administration: A 16 mg controlled-release subcutaneous afamelanotide implant or placebo every 60 days under the trial protocols

Limitations: The two trials used different sunlight windows and follow-up periods, relied on patient-recorded exposure, and studied a rare EPP population using a specific controlled-release implant. Results do not transfer to cosmetic tanning or unapproved formulations.

Controlled human studyPeer reviewed

Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial

Peer reviewed

PhaseInvestigational vitiligo trial

Population55 participants

Duration168 days

Design and population

Randomized multicenter trial of combination therapy versus narrowband UV-B phototherapy alone

Adults with stable or slowly progressive nonsegmental vitiligo affecting 15% to 50% of body surface area and Fitzpatrick skin types III to VI

Outcomes measured

Vitiligo Area Scoring Index
Vitiligo European Task Force score
Time to repigmentation
Adverse events

What was reported

The combination produced faster and greater average repigmentation than UV-B alone, with the clearest signal in darker studied skin phototypes.

Study administration and important limits

Study administration: Narrowband UV-B alone or narrowband UV-B plus four monthly 16 mg afamelanotide implants after a one-month phototherapy lead-in

Limitations: This was a small off-label combination study. It cannot isolate afamelanotide from UV-B, does not establish afamelanotide monotherapy, and did not support an FDA-approved vitiligo indication.

Other human evidencePeer reviewed

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria

Peer reviewed

PhasePostauthorization safety study

Population200 participants

DurationRepeated real-world follow-up; duration varied by participant

Design and population

Ongoing German observational registry and postauthorization safety study

German patients with EPP receiving afamelanotide

Outcomes measured

Treatment-emergent adverse events
EPP-specific quality of life
Treatment continuity

What was reported

Quality-of-life scores increased from baseline and 91% of participants who began treatment were still receiving it at the analysis cutoff. The reported safety pattern was consistent with the clinical-trial profile.

Study administration and important limits

Study administration: SCENESSE 16 mg implant according to the European product information

Limitations: Every analyzed participant was treated, so there was no untreated comparator. The study and registry received Clinuvel support, and several authors reported company employment, stock, or research support.

Other human evidencePeer reviewed

The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

Peer reviewed

PhaseMulticenter observational cohort

Population230 participants

DurationRoutine measurements collected from 2005 through 2021

Design and population

Longitudinal multicenter cohort comparing routine vitamin-D measurements across treatment-exposure groups

Adults with EPP in the Netherlands and Germany

Outcomes measured

Serum vitamin-D concentration
Vitamin-D deficiency prevalence

What was reported

Afamelanotide alone was not associated with a significant average vitamin-D increase. Cholecalciferol-containing groups had higher levels.

Study administration and important limits

Study administration: Observed exposure to no treatment, cholecalciferol, afamelanotide, or both

Limitations: This was observational and not randomized. It addresses vitamin-D laboratory values in EPP, not broader health outcomes or an individualized supplement plan.

Other human evidencePeer reviewed

Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria

Peer reviewed

PhaseRetrospective liver-outcome research

Population70 participants

DurationLongitudinal records including 2,933 liver tests, 1,186 protoporphyrin measurements, and 1,659 implants

Design and population

Retrospective repeated-measures observational study of laboratory records and implant exposure

Patients with EPP receiving clinical afamelanotide implants

Outcomes measured

Protoporphyrin IX concentration
Alanine aminotransferase
Bilirubin
Other liver-function tests

What was reported

More recent and more frequent implant exposure was associated with lower protoporphyrin and selected liver-test values in the statistical models.

Study administration and important limits

Study administration: Clinical afamelanotide implant exposure over time

Limitations: Retrospective association does not prove liver protection. Patient-level differences, season, indication, treatment selection, repeated testing, and reported company relationships may influence the findings.

Other human evidencePeer reviewed

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

Peer reviewed

PhasePostauthorization cohort

Population117 participants

DurationMedian follow-up of approximately 2 years

Design and population

Single-center prospective postauthorization safety and effectiveness cohort

Patients with EPP treated in routine clinical practice

Outcomes measured

Time spent outside
Phototoxic reactions
Disease-specific quality of life
Protective-clothing use
Adverse events

What was reported

During treatment, participants reported about 6.1 more hours outside per week and improved EPP-specific quality of life. Phototoxic reactions were reported as less painful, while their number and duration did not significantly change.

Study administration and important limits

Study administration: Afamelanotide implant in clinical practice

Limitations: This observational cohort had no untreated concurrent comparator, used self-reported outcomes, and cannot separate treatment effects from season, behavior, expectations, or selection into care.

Community

Experience reports stay separate from published evidence

Loading Community Intelligence…

Built by the community

Help strengthen the Afamelanotide experience record

Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.

Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.

Sources

Trace every major statement

FDA prescribing information

SCENESSE (afamelanotide) current U.S. prescribing information

2026-05-11 · NCT01605136; NCT00979745

FDA prescribing information

Peer reviewed

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria

2025-03-01 · PMID 40082741 · EUPAS13004 · DOI 10.1111/phpp.13012

Peer reviewed

Peer reviewed

The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

2024-04-18 · PMID 38634774 · DOI 10.1093/bjd/ljae148

Peer reviewed

Peer reviewed

Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria

2023-04-21 · PMID 37109595 · DOI 10.3390/life13041066

Peer reviewed

Peer reviewed

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

2020-03-18 · PMID 32186677 · DOI 10.1001/jamadermatol.2020.0352

Peer reviewed

Peer reviewed

Afamelanotide for Erythropoietic Protoporphyria

2015-07-02 · PMID 26132941 · NCT01605136; NCT00979745 · DOI 10.1056/NEJMoa1411481

Peer reviewed

Peer reviewed

Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial

2014-09-17 · PMID 25230094 · NCT01430195 · DOI 10.1001/jamadermatol.2014.1875

Peer reviewed

Profile identity

Afamelanotide

Aliases: Melanotan I, Melanotan-1, NDP-alpha-MSH, NDP-MSH, [Nle4,D-Phe7]-alpha-MSH, CUV1647, SCENESSE — product name

Targets: MC1R — predominant binding

Evidence maturity: Strong controlled human evidence and regulatory labeling for one rare-disease implant indication; supportive uncontrolled EPP cohorts; one small off-label vitiligo combination trial; observational liver and vitamin-D evidence

Regulatory status: FDA approved only as the SCENESSE 16 mg bioresorbable subcutaneous implant to increase pain-free light exposure in adults with EPP. Other products, formulations, populations, and uses are not covered by that approval.

Reviewed: July 25, 2026

Loading the next view…

Afamelanotide

Afamelanotide at a glance

Why people research it

What the evidence supports

Melanotan I, MT-1, and afamelanotide refer to the same synthetic alpha-MSH analogue, while SCENESSE is one specific regulated implant product.

Afamelanotide predominantly activates MC1R and increases eumelanin production independently of UV exposure.

SCENESSE has a narrow FDA-approved indication for increasing pain-free light exposure in adults with EPP.

Controlled EPP trials demonstrated more pain-free sunlight exposure and improved quality of life with the 16 mg implant.

Real-world EPP cohorts report improved time outdoors or quality of life, but they do not provide randomized confirmation.

A small randomized study found faster and greater vitiligo repigmentation when afamelanotide implants were added to narrowband UV-B.

Pigmentation is a known pharmacologic effect, not proof of cosmetic-tanning approval or protection from ordinary UV injury.

Important known safety findings include implant-site reactions, nausea, pigment changes, and rare serious hypersensitivity reactions.

The approved SCENESSE label describes a clinician-placed implant, not a self-injection or reconstituted peptide.

Observational liver findings in EPP are suggestive and do not establish an approved liver-protection benefit.

Afamelanotide treatment alone did not correct vitamin-D deficiency in a 230-person EPP cohort.

SCENESSE storage instructions do not create a general MT-1 reconstitution or stability standard.

What needs caution

Dosing & preparation

Afamelanotide · Scenesse implant label

Formulation & handling · Implant

SCENESSE controlled-release implant

How it works

Signals and targets

Proposed biological steps

How mature is the evidence?

Which product or study does this describe?

Study-by-study record

Afamelanotide for Erythropoietic Protoporphyria

Design and population

Outcomes measured

Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial

Design and population

Outcomes measured

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria

Design and population

Outcomes measured

The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

Design and population

Outcomes measured

Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria

Design and population

Outcomes measured

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

Design and population

Outcomes measured

Experience reports stay separate from published evidence

Help strengthen the Afamelanotide experience record

Keep the question moving

Trace every major statement

SCENESSE (afamelanotide) current U.S. prescribing information

German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria

The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

Afamelanotide for Erythropoietic Protoporphyria

Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial